Citigroup Inc. reissued their buy rating on shares of AstraZeneca plc (LON:AZN) in a research note released on Thursday, MarketBeat.com reports. They currently have a GBX 6,000 ($78.35) target price on the biopharmaceutical company’s stock.

AZN has been the topic of a number of other research reports. Liberum Capital reissued a buy rating and issued a GBX 5,100 ($66.60) target price on shares of AstraZeneca plc in a report on Thursday, April 27th. Barclays PLC reissued an overweight rating and issued a GBX 6,000 ($78.35) target price on shares of AstraZeneca plc in a report on Friday, April 28th. Deutsche Bank AG reissued a buy rating and issued a GBX 5,500 ($71.82) target price on shares of AstraZeneca plc in a report on Wednesday, March 15th. Societe Generale reissued a buy rating on shares of AstraZeneca plc in a report on Thursday, March 23rd. Finally, Credit Suisse Group reissued an underperform rating and issued a GBX 4,000 ($52.23) target price on shares of AstraZeneca plc in a report on Wednesday, April 19th. Three investment analysts have rated the stock with a sell rating, nine have given a hold rating and nine have assigned a buy rating to the stock. The company presently has an average rating of Hold and a consensus price target of GBX 5,251.80 ($68.58).

AstraZeneca plc (LON:AZN) opened at 5052.00 on Thursday. AstraZeneca plc has a 12 month low of GBX 3,996.00 and a 12 month high of GBX 5,520.00. The firm’s market cap is GBX 63.96 billion. The company has a 50-day moving average price of GBX 5,259.89 and a 200 day moving average price of GBX 4,769.91.

ILLEGAL ACTIVITY WARNING: “AstraZeneca plc’s (AZN) Buy Rating Reiterated at Citigroup Inc.” was reported by Daily Political and is the property of of Daily Political. If you are accessing this article on another domain, it was stolen and reposted in violation of United States and international trademark & copyright legislation. The original version of this article can be accessed at https://www.dailypolitical.com/2017/07/18/astrazeneca-plcs-azn-buy-rating-reiterated-at-citigroup-inc-2.html.

AstraZeneca plc Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Analyst Recommendations for AstraZeneca plc (LON:AZN)

Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.